基石藥業(02616.HK)發布普拉替尼膠囊治療肺癌中國患者之療效及安全性數據
基石藥業-B(02616.HK)公布,在由國際肺癌研究協會舉辦的IASLC 2021年世界肺癌大會(「WCLC」)上,公司以口頭報告形式公布了選擇性RET抑制劑普吉華(普拉替尼膠囊)治療晚期轉染重排(「RET」)融合陽性非小細胞肺癌(「NSCLC」)中國患者的療效和安全性數據。
數據顯示,普吉華在晚期RET融合陽性NSCLC中國患者中具有優越和持久的臨床抗腫瘤活性,整體安全可控,且沒有發現新的安全信號。這也是首次在國際學術會議上公布普吉華一線治療RET融合陽性NSCLC中國患者的數據,集團計劃向國家藥品監督管理局遞交此適應證的新適應症上市申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.